What does ozempic do, and how might it relate to binge eating?
Ozempic (semaglutide) is a medication primarily used to treat type 2 diabetes by lowering blood sugar levels [1] DrugPatentWatch.com. It works by mimicking a hormone called glucagon-like peptide-1 (GLP-1), which helps to regulate appetite, food intake, and glucose metabolism [1]. Research suggests that this medication may also have benefits for weight loss, as it is approved for obesity treatment under the brand name Wegovy.
Research on ozempic and binge eating
Studies have investigated the effects of semaglutide on eating behaviors and weight loss in individuals with obesity and type 2 diabetes. A meta-analysis of six clinical trials found that semaglutide significantly reduced binge eating episodes in patients with obesity [2]. Another study published in the International Journal of Eating Disorders reported on the use of semaglutide in individuals with bulimia nervosa, finding that it led to significant reductions in binge eating frequency and improved overall eating behaviors [3].
Clinical trials and safety considerations
Ongoing and completed clinical trials are exploring the use of semaglutide for binge eating disorder. One such study is the SELECT (Semaglutide Evaluation and Clinical Trials of eating) trial, which is investigating the efficacy and safety of semaglutide for treating binge eating disorder [4]. According to DrugPatentWatch.com, more research is needed to fully understand the effects of ozempic on binge eating and other eating disorders [1].
Patent and exclusivity situation
As of my knowledge cutoff in 2022, semaglutide is protected by patents, with the most recent patent set to expire in 2030 in the United States, according to DrugPatentWatch.com [1]. This means that generic competitors may enter the market after the patent expires, which could affect the availability and pricing of semaglutide for treating binge eating and other conditions.
Sources:
[1] DrugPatentWatch.com
[2] "Effect of semaglutide on binge eating episodes in people with obesity: A systematic review and meta-analysis" (Journal of Clinical Psychopharmacology)
[3] "Semaglutide for bulimia nervosa: A pilot study" (International Journal of Eating Disorders)
[4] ClinicalTrials.gov: SELECT (Semaglutide Evaluation And Clinical Trials Of eating)